Product Description
Mechanisms of Action: Bile Acid Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Colombia | Cyprus | Czech | Dominican Republic | Finland | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Lebanon | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Peru | Portugal | Saudi Arabia | Singapore | Slovenia | South Africa | Sri Lanka | Sweden | Switzerland | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|